WO2004074321A3 - Therapeutic gpcr targets in cancer - Google Patents

Therapeutic gpcr targets in cancer Download PDF

Info

Publication number
WO2004074321A3
WO2004074321A3 PCT/US2004/005000 US2004005000W WO2004074321A3 WO 2004074321 A3 WO2004074321 A3 WO 2004074321A3 US 2004005000 W US2004005000 W US 2004005000W WO 2004074321 A3 WO2004074321 A3 WO 2004074321A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
present
provides
sequences
detection
Prior art date
Application number
PCT/US2004/005000
Other languages
French (fr)
Other versions
WO2004074321A2 (en
Inventor
David W Morris
Marc S Malandro
Original Assignee
Sagres Discovery Inc
David W Morris
Marc S Malandro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/367,094 external-priority patent/US20040170982A1/en
Priority claimed from US10/388,838 external-priority patent/US20040180344A1/en
Priority claimed from US10/669,920 external-priority patent/US20060194265A1/en
Priority claimed from US10/737,318 external-priority patent/US20050202442A1/en
Application filed by Sagres Discovery Inc, David W Morris, Marc S Malandro filed Critical Sagres Discovery Inc
Priority to JP2006503729A priority Critical patent/JP2007524362A/en
Priority to EP04711946A priority patent/EP1592708A2/en
Priority to CA002516138A priority patent/CA2516138A1/en
Priority to AU2004213452A priority patent/AU2004213452A1/en
Priority to US10/545,778 priority patent/US20070149449A1/en
Publication of WO2004074321A2 publication Critical patent/WO2004074321A2/en
Publication of WO2004074321A3 publication Critical patent/WO2004074321A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. This invention relates to G-protein coupled receptor (GPCR) sequences. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.
PCT/US2004/005000 2003-02-14 2004-02-17 Therapeutic gpcr targets in cancer WO2004074321A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2006503729A JP2007524362A (en) 2003-02-14 2004-02-17 Therapeutic GPCR targets in cancer
EP04711946A EP1592708A2 (en) 2003-02-14 2004-02-17 Therapeutic gpcr targets in cancer
CA002516138A CA2516138A1 (en) 2003-02-14 2004-02-17 Therapeutic gpcr targets in cancer
AU2004213452A AU2004213452A1 (en) 2003-02-14 2004-02-17 Therapeutic GPCR targets in cancer
US10/545,778 US20070149449A1 (en) 2003-02-14 2004-02-17 Therapeutic targets in cancer

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US10/367,094 US20040170982A1 (en) 2003-02-14 2003-02-14 Novel therapeutic targets in cancer
US10/367,094 2003-02-14
US10/388,838 2003-03-14
US10/388,838 US20040180344A1 (en) 2003-03-14 2003-03-14 Novel therapeutic targets in cancer
US10/669,920 US20060194265A1 (en) 2001-10-23 2003-09-23 Novel therapeutic targets in cancer
US10/669,920 2003-09-23
US10/737,318 2003-12-15
US10/737,318 US20050202442A1 (en) 2003-12-15 2003-12-15 Novel therapeutic targets in cancer

Publications (2)

Publication Number Publication Date
WO2004074321A2 WO2004074321A2 (en) 2004-09-02
WO2004074321A3 true WO2004074321A3 (en) 2005-01-13

Family

ID=32913217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/005000 WO2004074321A2 (en) 2003-02-14 2004-02-17 Therapeutic gpcr targets in cancer

Country Status (6)

Country Link
US (1) US20070149449A1 (en)
EP (2) EP1592708A2 (en)
JP (2) JP2007524362A (en)
AU (1) AU2004213452A1 (en)
CA (1) CA2516138A1 (en)
WO (1) WO2004074321A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
KR101137019B1 (en) 2009-05-25 2012-05-24 한국생명공학연구원 A novel g protein coupled receptor and a use thereof
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
KR101535262B1 (en) * 2012-08-07 2015-07-08 한국생명공학연구원 High Throughput Screening System for Identification of Agonist and Antagonist of Human Orphan G-Protein coupled receptor
AU2019256383A1 (en) 2018-04-17 2020-11-26 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
JP2022049406A (en) 2020-09-16 2022-03-29 キオクシア株式会社 Magnetic storage device

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107475A (en) * 1992-11-17 2000-08-22 Icos Corporation Seven transmembrane receptors
WO2001072830A2 (en) * 2000-03-31 2001-10-04 Ipf Pharmaceuticals Gmbh Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
WO2002057497A2 (en) * 2001-01-18 2002-07-25 The Regents Of The University Of California High through-put cloning of protooncogenes
WO2003008583A2 (en) * 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
EP1365034A2 (en) * 2002-05-21 2003-11-26 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4956453A (en) 1985-12-06 1990-09-11 Cetus Corporation Anti-human ovarian cancer immunotoxins and methods of use thereof
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5359100A (en) 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5594113A (en) 1988-06-23 1997-01-14 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0454781B1 (en) 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
ES2055907T3 (en) 1989-03-07 1994-09-01 Genentech Inc COVALENT CONJUGATES OF LIPIDS AND OLIGONUCLEOTIDES.
ATE165516T1 (en) 1989-03-21 1998-05-15 Vical Inc EXPRESSION OF EXOGENEOUS POLYNUCLEOTIDE SEQUENCES IN VERTEBRATES
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc GENERATION OF XENOGENIC ANTIBODIES
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
DE69130612T2 (en) 1990-07-27 1999-05-06 Chiron Corp., Emeryville, Calif. LARGE COMB BRANCHED POLYNUCLEOTIDES
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3337214B2 (en) 1990-12-20 2002-10-21 アーチ・ディベロップメント・コーポレーション Regulation of gene expression by ionizing radiation
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
ATE237694T1 (en) 1991-08-20 2003-05-15 Us Gov Health & Human Serv ADENOVIRUS-MEDIATED GENE TRANSFER INTO THE GASTROINTESTINAL TRACT
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
CA2128616A1 (en) 1992-01-23 1993-08-05 Gary H. Rhodes Ex vivo gene transfer
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
WO1993022443A1 (en) 1992-04-24 1993-11-11 Sri International In vivo homologous sequence targeting in eukaryotic cells
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California Methods and compositions for targeting specific tissue.
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
ES2188612T3 (en) 1993-04-22 2003-07-01 Skyepharma Inc MULTIVESICULAR CYCLODEXTRINE LIPOSOMES TO ENCAPSULATE PHARMACOLOGICAL COMPOUNDS AND METHODS FOR USE.
CA2166118C (en) 1993-06-24 2007-04-17 Frank L. Graham Adenovirus vectors for gene therapy
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
EP0716148B1 (en) 1993-09-15 2004-01-02 Chiron Corporation Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
HU223733B1 (en) 1993-10-25 2004-12-28 Canji, Inc. Rekombinant adenoviral vector and methods of use
JP3002702B2 (en) 1993-11-16 2000-01-24 スカイファーム インコーポレーテッド Vesicles with controlled release of active substance
US5681697A (en) 1993-12-08 1997-10-28 Chiron Corporation Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
JP4303315B2 (en) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド Non-crossing retroviral vector
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
WO1997027213A1 (en) 1996-01-23 1997-07-31 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and rna molecules
EP0953052B1 (en) 1996-05-06 2009-03-04 Oxford BioMedica (UK) Limited Crossless retroviral vectors
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
AU3316600A (en) * 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US6406840B1 (en) 1999-12-17 2002-06-18 Biomosaic Systems, Inc. Cell arrays and the uses thereof
EP1358327A2 (en) * 2001-01-11 2003-11-05 Curagen Corporation Proteins and nucleic acids encoding same
US20030044409A1 (en) * 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
ATE503023T1 (en) * 2001-06-18 2011-04-15 Rosetta Inpharmatics Llc DIAGNOSIS AND PROGNOSIS OF BREAST CANCER PATIENTS
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
US20050202442A1 (en) 2003-12-15 2005-09-15 Morris David W. Novel therapeutic targets in cancer
US20040180344A1 (en) 2003-03-14 2004-09-16 Morris David W. Novel therapeutic targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107475A (en) * 1992-11-17 2000-08-22 Icos Corporation Seven transmembrane receptors
WO2001072830A2 (en) * 2000-03-31 2001-10-04 Ipf Pharmaceuticals Gmbh Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
WO2002057497A2 (en) * 2001-01-18 2002-07-25 The Regents Of The University Of California High through-put cloning of protooncogenes
WO2003008583A2 (en) * 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
EP1365034A2 (en) * 2002-05-21 2003-11-26 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALLEN L F ET AL: "G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the alpha 1B-adrenergic receptor enhances mitogenesis and tumorigenicity.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 15 DEC 1991, vol. 88, no. 24, 15 December 1991 (1991-12-15), pages 11354 - 11358, XP002292391, ISSN: 0027-8424 *
HOEPKEN UTA E ET AL: "Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs", BLOOD, vol. 99, no. 4, 15 February 2002 (2002-02-15), pages 1109 - 1116, XP002292389, ISSN: 0006-4971 *
MUELLER ANJA ET AL: "Involvement of chemokine receptors in breast cancer metastasis", NATURE (LONDON), vol. 410, no. 6824, 1 March 2001 (2001-03-01), pages 50 - 56, XP002292390, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
JP2007524362A (en) 2007-08-30
EP2058408A3 (en) 2009-09-09
EP2058408A2 (en) 2009-05-13
US20070149449A1 (en) 2007-06-28
JP2009207497A (en) 2009-09-17
CA2516138A1 (en) 2004-09-02
WO2004074321A2 (en) 2004-09-02
AU2004213452A1 (en) 2004-09-02
EP1592708A2 (en) 2005-11-09

Similar Documents

Publication Publication Date Title
WO2004074320A3 (en) Therapeutic targets in cancer
WO2005031001A3 (en) Novel therapeutic targets in cancer
WO2005104810A3 (en) Novel therapeutic targets in cancer
WO2004058146A3 (en) Novel compositions and methods in cancer
WO2004060304A3 (en) Novel compositions and methods in cancer
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
PH12012501006A1 (en) Compositions and methods relating to anti-igf-1 receptor antibodies
WO2008010101A8 (en) Antagonist antibody against epha2 for the treatment of cancer
WO2005107396A3 (en) Novel compositions and methods in cancer
HK1082200A1 (en) Compositions and methods for the therapy of inflammatory bowel disease
SG141243A1 (en) Anti-igf-i receptor antibody
WO2006084226A3 (en) Antibodies that bind to epha2 and methods of use thereof
WO2004078938A3 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2009019365A3 (en) Ezrin assay method for the in vitro diagnosis of colorectal cancer
WO2009029591A3 (en) Monoclonal antibody which binds met in formalin-fixed and paraffin-embedded tissues and related methods
WO2007149948A3 (en) Compositions and methods for diagnosis and treatment of tumors
WO2006038955A3 (en) Novel therapeutic targets in cancer
WO2003080808A3 (en) Novel compositions and methods in cancer
WO2004074321A3 (en) Therapeutic gpcr targets in cancer
WO2007107774A3 (en) Integrin alpha-10 subunit as therapeutic target and diagnostic/prognostic marker for cancer
WO2009052255A3 (en) Novel therapeutic targets in bowel disease
WO2004060301A3 (en) Novel compositions and methods in cancer
WO2008124170A3 (en) SELECTION OF HUMAN TNFα SPECIFIC ANTIBODIES
WO2004101762A3 (en) Detection and treatment of cancers of the colon
WO2004094612A3 (en) Cancer specific monoclonal antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2516138

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006503729

Country of ref document: JP

Ref document number: 2004213452

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004213452

Country of ref document: AU

Date of ref document: 20040217

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004213452

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004711946

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004711946

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007149449

Country of ref document: US

Ref document number: 10545778

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10545778

Country of ref document: US